FAKTOR OPTIONSSCHEIN - STAAR SURGICAL Share Price

Certificat

DE000PG4CSR8

Delayed Deutsche Boerse AG 01:20:45 20/05/2024 pm IST
1.5 EUR -7.98% Intraday chart for FAKTOR OPTIONSSCHEIN - STAAR SURGICAL
Current month-39.41%
1 month-42.20%
Date Price Change
20/24/20 1.5 -7.98%
17/24/17 1.63 +1.24%
16/24/16 1.61 -4.73%
15/24/15 1.69 -7.14%
14/24/14 1.82 +1.11%

Delayed Quote Deutsche Boerse AG

Last update May 20, 2024 at 01:20 pm IST

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying STAAR SURGICAL COMPANY
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PG4CSR
ISINDE000PG4CSR8
Date issued 24/10/2023
Strike 42.62 $
Maturity Unlimited
Parity 1 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.63
Lowest since issue 0.56
Spread 0.33
Spread %18.03%

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Sector
-
More about the company

Ratings for STAAR Surgical Company

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: STAAR Surgical Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
42.7 USD
Average target price
52.31 USD
Spread / Average Target
+22.51%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW